CEO Doug Biehn sits down with Nasdaq’s Leigh Hixon to share Octave’s vision of transforming neurodegenerative disease care through precision medicine. Watch Now

Octave at ACTRIMS Forum 2024

Thursday, February 29 – Saturday, March 2
West Palm Beach, Florida

We loved connecting with MS experts from around the country at ACTRIMS 2024. We’re excited to share our posters and how we are changing the paradigm of care in multiple sclerosis (MS).

Our 2024 ACTRIMS Posters

Posters that support our Biology Solution

Learn more about our Biology Solution

Comparison of Natalizumab Ocrelizumab and Diroximel Fumarate in RRMs Patients Stable on Therapy to Characterize Proteomic Radiomic and Clinical Trajectories: Study Design

Real-World Utilization of a Proteomic Biomarker Panel for Assessing Multiple Sclerosis Disease Activity in an Academic Multiple Sclerosis Clinic with a Diverse Patient Population

Safety and Effectiveness of Cladribine Tablets After Treatment With Natalizumab (CLADRINA) Trial – Interim Analysis

Posters that support our Imaging Solution

Learn more about our Imaging Solution

Evaluating the Impact of Manual Editing on Automated MRI Lesion Segmentation in Multiple Sclerosis

Discrepancies in the Detection of Salient MS Lesion Counts Between Neuroradiologists and Manually Corrected Automated Lesion Segmentation

Posters that support our Precision Care Solution

Learn more about our Precision Care Solution

Measuring Outcomes and Value: an Integrated, Novel Solution for Generating insights in MS (MOVING MS)

Improving Patient Outcomes Through a Comprehensive Care Platform in MOVING-MS – A Case Study

To learn more about our science, view all of our past posters and publications.

Check out Octave at ACTRIMS 2024, West Palm Beach